915087-32-0

Basic information

• Product Name: 4-(2-CYANOPROPAN-2-YLAMINO)-2-FLUORO-N-METHYLBENZAMIDE
• Synonyms: 4-(2-CYANOPROPAN-2-YLAMINO)-2-FLUORO-N-METHYLBENZAMIDE;BenzaMide, 4-[(1-cyano-1-Methylethyl)aMino]-2-fluoro-N-Methyl-;4. 4-((2-cyanopropan-2-yl)aMino)-2-fluoro-N-MethylbenzaMide;4-[(1-Cyano-1-Methylethyl)aMino]-2-fluoro-N-MethylbenzaMide
• CAS NO: 915087-32-0
• Molecular Formula: C₁₂H₁₄FN₃O
• Molecular Weight: 235.26
• Mol File: 915087-32-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 413.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• PKA: 14.29±0.46(Predicted)
• CAS DataBase Reference: 4-(2-CYANOPROPAN-2-YLAMINO)-2-FLUORO-N-METHYLBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-CYANOPROPAN-2-YLAMINO)-2-FLUORO-N-METHYLBENZAMIDE(915087-32-0)
• EPA Substance Registry System: 4-(2-CYANOPROPAN-2-YLAMINO)-2-FLUORO-N-METHYLBENZAMIDE(915087-32-0)

Safety Data

• Hazardous Substances Data: 915087-32-0(Hazardous Substances Data)

Usage

Description

4-(2-CYANOPROPAN-2-YLAMINO)-2-FLUORO-N-METHYLBENZAMIDE is a chemical compound with a complex structure that features a cyano group, a fluorine atom, and a methylbenzamide moiety. It is known for its potential applications in the development of pharmaceuticals, particularly in the area of androgen receptor antagonists.

Uses

Used in Pharmaceutical Industry:
4-(2-CYANOPROPAN-2-YLAMINO)-2-FLUORO-N-METHYLBENZAMIDE is used as a key intermediate in the synthesis of thiohydantoin androgen receptor antagonists. These antagonists are specifically designed for the treatment of castration-resistant prostate cancer, a condition where the cancer continues to grow despite low levels of testosterone.
Additionally, this compound is utilized in the preparation of imidazolidinedione compounds, which also act as androgen receptor antagonists. These antagonists are beneficial in the treatment of various diseases, including prostate cancer, by targeting the androgen receptor and inhibiting its activity, thus limiting the growth of cancer cells.

Upstream product

• 1427-07-2 2-fluoro-4-nitrotoluene 
• 749927-69-3 4-bromo-2-fluoro-N-methylbenzanamide 
• 19355-69-2 2-amino-2-cyanopropane 
• 915087-25-1 2-fluoro-N-methyl-4-amino-benzamide 
• 7677-24-9 trimethylsilyl cyanide 
• 915087-24-0 2-fluoro-N-methyl-4-nitro-benzamide 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 
• 67-64-1 acetone 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 

Downstream Products

• 915087-33-1 enzalutamide 
• 1463530-11-1 4-(3-(4-cyano-3-(perfluoropropan-2-yl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide 
• 1272719-00-2 4-[3-(4-cyano-2-fluoro-3-trifluoromethyl-phenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide 
• 1272718-99-6 4-[3-(3-chloro-4-cyano-2-fluoro-phenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide 
• 1272719-10-4 4-[3-(4-cyano-2-fluoro-3-methoxy-phenyl)-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide 

Relevant articles and documents

Prostatic cancer treatment medicine

The invention relates to a compound with a prostatic cancer treatment function and nontoxic pharmaceutically acceptable salt of the compound. The structure of the compound is as shown in a formula I,wherein X is C or N, R1 is alkyl of C1-C3 or halogen substituted alkyl, R2 is alkyl of C1-C3 and halogen substituted alkyl or halogen, R3 and R4 are independently selected from H, alkyl and substituted alkyl, and R3 and R4 are connected to form cycloalkyl. The compound has high inhibiting effects on in-situ prostate cancer and transfer of the prostate cancer, and eclamptogenic side effects are lower.

Effect of N-methyl deuteration on pharmacokinetics and pharmacodynamics of enzalutamide

Enzalutamide, a second-generation antiandrogen, has been developed for the treatment of castration-resistance prostate cancer. We synthesized the deuterated analogues 6 and found that it showed higher drug exposure and thus stronger antitumor potency in preclinical settings. Compound 6 is being developed clinically for the potential to be differentiated from enzalutamide through reduced dosages and a higher safety margin.

IMIDAZOLE DIKETONE COMPOUND AND USE THEREOF

Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. Said imidazolidinedione compounds possess androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne.